IP Library › Granted Patent US 12,344,669
Granted Patent B2
US 12,344,669 · App. 17/490,735 · Granted Jul 1, 2025

Anti-CD47 monoclonal antibody and use thereof

Inventors: Xiao Feng (Jilin, CN); Lei Jin (Jilin, CN); Liang Xiao (Jilin, CN); Tao Wang (Jilin, CN); Suofu Qin (Jilin, CN)
Assignee: CHANGCHUN GENESCIENCE PHARMACEUTICAL CO., LTD.
C07K16/2803A61P35/02C07K16/30G01N33/57484A61K2039/505
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,344,669
App. No.
17/490,735
Granted
Jul 1, 2025
Kind
B2
Abstract

An anti-CD47 monoclonal antibody and use thereof. The provided anti-CD47 monoclonal antibody can effectively inhibit tumor growth. Blocking human SIRP and human CD47 signals may enhance macrophage phagocytosis of tumor cells, prevent the tumor cells from escaping a tumor immune defense system, and have an anti-tumor function. Blocking association between the CD47 on a tumor cell surface and the SIRP on a macrophage surface may block a “do not eat me” signal from the tumor cells, promoting tumor cell recognition and uptake of macrophages, and thereby facilitating tumor cells to be phagocytosed. The association between the CD47 on a tumor cell surface and the SIRP on a macrophage surface is a common “do not eat me” signal. The anti-CD47 antibody, as a very promising target in the tumor immune system, will play a powerful and effective role in human cancer therapy.

Claims (25)

1. An anti-CD47 monoclonal antibody, comprising:

hypervariable regions including an amino acid sequence having a heavy chain variable region and a light chain variable region,

wherein, the hypervariable regions of the heavy chain variable region are HVR-H1, HVR-H2, and HVR-H3, the hypervariable region HVR-H1 sequence being represented by SEQ ID NO: 48, the HVR-H2 sequence being represented by SEQ ID NO: 49; and the HVR-H3 sequence being represented by SEQ ID NO: 50; and

wherein the hypervariable regions of the light chain variable region are HVR-L1, HVR-L2, and HVR-L3, the hypervariable region HVR-L1 sequence being represented by SEQ ID NO: 57; the HVR-L2 sequence being represented by SEQ ID NO: 58; and the HVR-L3 sequence being represented by SEQ ID NO: 59.

2. An anti-CD47 monoclonal antibody, comprising:

hypervariable regions including a heavy chain variable region and a light chain variable region,

wherein the hypervariable regions of the heavy chain variable region are HVR-H1, HVR-H2, and HVR-H3, the hypervariable region HVR-H1 sequence being represented by SEQ ID NO: 45, the HVR-H2 sequence being represented by SEQ ID NO: 46; and the HVR-H3 sequence being represented by SEQ ID NO: 47; and

wherein the hypervariable regions of the light chain variable region are HVR-L1, HVR-L2, and HVR-L3, the hypervariable region HVR-L1 sequence being represented by SEQ ID NO: 54; the HVR-L2 sequence being represented by SEQ ID NO: 55; and the HVR-L3 sequence being represented by SEQ ID NO: 56.

3. An anti-CD47 monoclonal antibody, comprising:

hypervariable regions including a heavy chain variable region and a light chain variable region,

wherein, the hypervariable regions of the heavy chain variable region are HVR-H1, HVR-H2, and HVR-H3, the hypervariable region HVR-H1 sequence being represented by SEQ ID NO: 51, the HVR-H2 sequence being represented by SEQ ID NO: 52; and the HVR-H3 sequence being represented by SEQ ID NO: 53; and

wherein the hypervariable regions of the light chain variable region are HVR-L1, HVR-L2, and HVR-L3, the hypervariable region HVR-L1 sequence being represented by SEQ ID NO: 60; the HVR-L2 sequence being represented by SEQ ID NO: 61; and the HVR-L3 sequence being represented by SEQ ID NO: 62.

4. The anti-CD47 monoclonal antibody according to claim 1 , wherein, the heavy chain type is IgG1, IgG3 or IgM; and the light chain type is κ.

5. A hybridoma cell strain, which produces the anti-CD47 monoclonal antibody according to claim 1 .

6. A preparation method of the anti-CD47 monoclonal antibody according to claim 1 , wherein, the preparation method comprises:

Step 1: after immunizing a mouse with the antigen of an amino acid sequence represented by SEQ ID Nos: 29 to 32, obtaining spleen cells of the mouse;

Step 2: fusing the spleen cells with myeloma cells, screening for a hybridoma cell strain capable of binding to CD47, and culturing the cell strain in vitro to obtain the anti-CD47 monoclonal antibody.

7. A combination, which is made by marking the anti-CD47 monoclonal antibody according to claim 1 with a chemical or biological marker.

8. The combination according to claim 7 , wherein, the chemical marker is an isotope, an immunotoxin and/or a chemical drug; and the biological marker is biotin, avidin or an enzyme label.

9. A conjugate, which is prepared by coupling the anti-CD47 monoclonal antibody according to of claim 1 to a solid medium or a semi-solid medium.

10. A kit, wherein, the kit comprises the anti-CD47 monoclonal antibody according to claim 1 .

11. A medicament, wherein, it comprises the anti-CD47 monoclonal antibody according to claim 1 .

12. The anti-CD47 monoclonal antibody according to claim 1 , wherein the anti-CD47 monoclonal antibody is in a formulation for increasing macrophage phagocytosis of tumor cells, the formulation having a concentration of the anti-CD47 monoclonal antibody sufficient to block binding of CD47 on tumor cells to signal regulatory protein α on a macrophage.

13. The anti-CD47 monoclonal antibody according to claim 2 , wherein the anti-CD47 monoclonal antibody is in a formulation for increasing macrophage phagocytosis of tumor cells, the formulation having a concentration of the anti-CD47 monoclonal antibody sufficient to block binding of CD47 on tumor cells to signal regulatory protein α on a macrophage.

14. The anti-CD47 monoclonal antibody according to claim 3 , wherein the anti-CD47 monoclonal antibody is in a formulation for increasing macrophage phagocytosis of tumor cells, the formulation having a concentration of the anti-CD47 monoclonal antibody sufficient to block binding of CD47 on tumor cells to signal regulatory protein α on a macrophage.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2021
From: FENG, XIAO; JIN, LEI; XIAO, LIANG; WANG, TAO; QIN, SUOFU
To: CHANGCHUN GENESCIENCE PHARMACEUTICAL CO., LTD.
Reel/Frame 057659/0488 →
Priority Claims (1)
CN 201610436519.3 · Jun 17, 2016 · national
Continuity (2)
Continuation In Part 16310748
Related Publication 20220089727A1 · Mar 24, 2022
References Cited (37)
US 11155632B2 · Feng · 2021 [cited by examiner]
US 20110105380A1 · Discher et al. · 2011 [cited by applicant]
US 20200079869A1 · Feng et al. · 2020 [cited by applicant]
AU 2017284157B2 · 2017 [cited by applicant]
EP 3473649A1 · 2019 [cited by applicant]
JP 2015508072A · 2015 [cited by applicant]
WO 2014087248A2 · 2014 [cited by applicant]
WO 2014124028A1 · 2014 [cited by applicant]
WO 2015191861A1 · 2015 [cited by applicant]
WO 2016081423A1 · 2016 [cited by applicant]
WO 2017215585A1 · 2017 [cited by applicant]
3022484, Office Action issued by the Canadian Intellectual Property Office on Nov. 22, 2021. [cited by applicant]
Office Action for Canadian Patent Application No. 3,022,484 issued by the Canadian Intellectual property Office on Dec. 5, 2022. [cited by applicant]
International Search Report of Priority Documents CN201610436519.3 on Apr. 1, 2019, not translated. [cited by applicant]
The First Office Action for Chinese Patent Application No. 201610436519.3 issued by the Chinese Patent Office on Apr. 1, 2019, not translated. [cited by applicant]
The Search Report for Chinese Patent Application No. 2016104365193 issued by the Chinese Patent Office on Mar. 25, 2019. [cited by applicant]
Office Action for Australian Patent Application No. 2017284157 issued by the Australian Government on Jul. 8, 2019, Examination report No. 1. [cited by applicant]
Office Action for Canadian Patent Application No. 3,022,484 issued by the Canadian Intellectual Property Office on Sep. 11, 2019. [cited by applicant]
Office Action for Japanese Patent Application No. 2018-558409 issued by the Japanese Patent Office on Dec. 24, 2019, Not translated. [cited by applicant]
Office Action for Australian Patent Application No. 2017284157 issued by the Australian Government on Jan. 8, 2020. [cited by applicant]
The Second Office Action for Chinese Patent Application No. 201610436519.3 issued by the Chinese Patent Office on Jun. 19, 2019, not translated. [cited by applicant]
Office Action for Korean Patent Application No. 10-2018-7037214 issued by the Korean Patent Office on Mar. 23, 2020, not translated. [cited by applicant]
Extended European Search Report for European Patent Application No. 17812696.7 issued by the European Patent Office on May 18, 2020. [cited by applicant]
The partial supplementary European search report for European Patent Application No. 17812696.7 issued by the European Patent Office on Jan. 20, 2020. [cited by applicant]
Office Action for Australian Patent Application No. 2017284157 issued by the Australian Government on May 20, 2020, Examination report No. 3. [cited by applicant]
Restriction Requirement for U.S. Appl. No. 16/310,748 issued by the USPTO on Jun. 30, 2020. [cited by applicant]
Notice of Allowance for Australian Patent Application No. 2017284157 issued by the Australian Government on Jul. 10, 2020, Notice of Acceptance. [cited by applicant]
Notice of Allowance for Japanese Patent Application No. 2018-558409 issued by the Japanese Patent Office on Sep. 29, 2020. [cited by applicant]
Office Action for Canadian Patent Application No. 3,022,484 issued by the Canadian Intellectual Property Office on Oct. 5, 2020. [cited by applicant]
Decision of Rejection for Korean Patent Application No. 10-2018-7037214 issued by the Korean Patent Office on Oct. 23, 2020. [cited by applicant]
Office Action for Korean Patent Application No. 10-2018-7037214 issued by the Korean Patent Office on Dec. 3, 2020, not translated. [cited by applicant]
Office Action for U.S. Appl. No. 16/310,748 issued by the USPTO on Dec. 11, 2020. [cited by applicant]
Notice of Allowance for Korean Patent Application No. 10-2018-7037214 issued by the Korean Patent Office on Feb. 18, 2021. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/310,748 issued by the USPTO on Jun. 23, 2021. [cited by applicant]
Office Action for Canadian Patent Application No. 3,022,484 issued by the Canadian Intellectual Property Office on Nov. 22, 2021. [cited by applicant]
Office Action for European Patent Application No. 17812696.7 issued by the European Patent Office on Mar. 15, 2023. [cited by applicant]
Office Action for Canadian Patent Application No. 3,022,484 issued by the Canadian Intellectual Property Office on Sep. 11, 2023. [cited by applicant]